amlodipine has been researched along with Chronic Kidney Diseases in 28 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 9.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| " We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease." | 9.17 | L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013) |
| "to study effectiveness of a fixed combination of perindopril arginine and amlodipine besylate for the treatment of arterial hypertension with concomitant chronic cardiac insufficiency and signs of chronic kidney disease Materials and methods: 53 (44." | 7.81 | [EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE]. ( Borovkova, NY; Kuznetsova, TE, 2015) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 7.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| " The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function." | 6.75 | Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. ( Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 6.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 5.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| " We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease." | 5.17 | L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013) |
| " The swelling was caused by the antihypertensive amlodipine, which he used because of arterial hypertension due to a chronic kidney disease." | 4.31 | [Swelling of the labial gingiva of the teeth]. ( de Visscher, JGAM; Raaff, PI; van der Meij, EH, 2023) |
| " The medical records of diabetic cats were searched for the keywords 'hypertension', 'blood pressure', 'amlodipine', 'benazepril' and 'telmisartan' to identify cats with SH, which was defined as systemic arterial blood pressure (SABP) ⩾160 mmHg, documented at least twice, over several days." | 4.31 | Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension. ( Hess, RS; Williams, JG, 2023) |
| "Aim To study the condition of coronary vasculature by data of coronarography (CG) in patients with chronic ischemic heart disease (IHD) and arterial hypertension (AH) associated with stage 2-4 chronic kidney disease (CKD) and to evaluate the effect of a 12-week complex treatment with perindopril or with a combination of perindopril/amlodipine on changes in vascular wall stiffness, endothelial function, and structure and function parameters in this patient category after coronary stenting." | 4.02 | [Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting]. ( Barbashina, TA; Gavriljuk, EV; Mal, GS; Pribylov, CA; Pribylov, VS; Pribylova, NN; Yakovleva, MV, 2021) |
| "to study effectiveness of a fixed combination of perindopril arginine and amlodipine besylate for the treatment of arterial hypertension with concomitant chronic cardiac insufficiency and signs of chronic kidney disease Materials and methods: 53 (44." | 3.81 | [EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE]. ( Borovkova, NY; Kuznetsova, TE, 2015) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 3.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| " The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function." | 2.75 | Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. ( Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 2.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "amlodipine was associated with lower BPV than other CCBs for both hypertensive patients and hypertensive patients with comorbidity." | 1.48 | Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. ( Dong, P; Li, L; Lin, Y; Liu, D; Xie, X; Yang, J; Zhang, L, 2018) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| " The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs." | 1.43 | Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. ( Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 20 (71.43) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Pribylova, NN | 1 |
| Yakovleva, MV | 1 |
| Pribylov, CA | 1 |
| Barbashina, TA | 1 |
| Gavriljuk, EV | 1 |
| Mal, GS | 1 |
| Pribylov, VS | 1 |
| Raaff, PI | 1 |
| van der Meij, EH | 1 |
| de Visscher, JGAM | 1 |
| Williams, JG | 1 |
| Hess, RS | 1 |
| Sofy, AA | 1 |
| Abdelsattar, AT | 1 |
| Mohammed, OM | 1 |
| Shareef, MA | 1 |
| Alamodi, AA | 1 |
| Nso, N | 1 |
| Payton, M | 1 |
| Masoud, AT | 1 |
| Lawson, JS | 1 |
| Jepson, RE | 1 |
| Zhang, L | 1 |
| Yang, J | 1 |
| Li, L | 1 |
| Liu, D | 1 |
| Xie, X | 1 |
| Dong, P | 1 |
| Lin, Y | 1 |
| Khatir, DS | 1 |
| Pedersen, M | 1 |
| Ivarsen, P | 1 |
| Christensen, KL | 1 |
| Jespersen, B | 1 |
| Buus, NH | 1 |
| Oguzhan, N | 1 |
| Cilan, H | 1 |
| Sipahioglu, M | 1 |
| Unal, A | 1 |
| Kocyigit, I | 1 |
| Kavuncuoglu, F | 1 |
| Arikan, T | 1 |
| Akpek, M | 1 |
| Elcik, D | 1 |
| Sahin, O | 1 |
| Gulme, E | 1 |
| Pala, C | 1 |
| Tokgoz, B | 1 |
| Utas, C | 1 |
| Oguzhan, A | 1 |
| Oymak, O | 1 |
| Chrysant, SG | 2 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Cutlip, DE | 1 |
| Jamerson, K | 1 |
| Henrich, W | 1 |
| Reid, DM | 1 |
| Cohen, DJ | 1 |
| Matsumoto, AH | 1 |
| Steffes, M | 1 |
| Jaff, MR | 1 |
| Prince, MR | 1 |
| Lewis, EF | 1 |
| Tuttle, KR | 1 |
| Shapiro, JI | 1 |
| Rundback, JH | 1 |
| Massaro, JM | 1 |
| D'Agostino, RB | 1 |
| Dworkin, LD | 1 |
| Sweiss, N | 1 |
| Sharma, K | 1 |
| Azushima, K | 1 |
| Uneda, K | 1 |
| Tamura, K | 1 |
| Wakui, H | 1 |
| Ohsawa, M | 1 |
| Kobayashi, R | 1 |
| Dejima, T | 1 |
| Kanaoka, T | 1 |
| Maeda, A | 1 |
| Toya, Y | 1 |
| Umemura, S | 1 |
| Ando, K | 2 |
| Nitta, K | 1 |
| Rakugi, H | 1 |
| Nishizawa, Y | 1 |
| Yokoyama, H | 1 |
| Nakanishi, T | 1 |
| Kashihara, N | 1 |
| Tomita, K | 1 |
| Nangaku, M | 2 |
| Takahashi, K | 2 |
| Isshiki, M | 2 |
| Shimosawa, T | 1 |
| Fujita, T | 2 |
| Kato, H | 1 |
| Shiraishi, T | 1 |
| Ueda, S | 1 |
| Kubo, E | 1 |
| Shima, T | 1 |
| Nagura, M | 1 |
| Yano, H | 1 |
| Izumikawa, Y | 1 |
| Shimada, M | 1 |
| Tomioka, S | 1 |
| Nosaka, H | 1 |
| Kojima, K | 1 |
| Tanemoto, M | 1 |
| Uchida, S | 3 |
| Hayashi, M | 1 |
| Kawamura, T | 1 |
| Kuwahara, M | 1 |
| Iino, Y | 1 |
| Kuznetsova, TE | 1 |
| Borovkova, NY | 1 |
| Borovkova, NJ | 1 |
| Kuznecova, TE | 1 |
| Borovkov, NN | 1 |
| Kovaleva, GV | 1 |
| Whittle, J | 1 |
| Lynch, AI | 1 |
| Tanner, RM | 1 |
| Simpson, LM | 1 |
| Davis, BR | 1 |
| Rahman, M | 1 |
| Whelton, PK | 1 |
| Oparil, S | 1 |
| Muntner, P | 1 |
| Koya, Y | 1 |
| Machi, Y | 1 |
| Shobu, Y | 1 |
| Namiki, N | 1 |
| Kotegawa, T | 1 |
| Guo, LL | 1 |
| Pan, Y | 1 |
| Jin, HM | 1 |
| Kaneshiro, Y | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Kinouchi, K | 1 |
| Itoh, H | 1 |
| Miyagawa, K | 1 |
| Dohi, Y | 1 |
| Nakazawa, A | 1 |
| Sugiura, T | 1 |
| Yamashita, S | 1 |
| Sato, K | 1 |
| Kimura, G | 1 |
| Kobayashi, N | 1 |
| Ishimitsu, T | 1 |
| Takenaka, T | 1 |
| Seto, T | 1 |
| Okayama, M | 1 |
| Kojima, E | 1 |
| Nodaira, Y | 1 |
| Sueyoshi, K | 1 |
| Kikuta, T | 1 |
| Watanabe, Y | 1 |
| Inoue, T | 1 |
| Takane, H | 1 |
| Ohno, Y | 1 |
| Suzuki, H | 2 |
| Soeki, T | 1 |
| Kitani, M | 1 |
| Kusunose, K | 1 |
| Yagi, S | 1 |
| Taketani, Y | 1 |
| Koshiba, K | 1 |
| Wakatsuki, T | 1 |
| Orino, S | 1 |
| Kawano, K | 1 |
| Sata, M | 1 |
| Abe, M | 1 |
| Maruyama, N | 1 |
| Inoshita, A | 1 |
| Yoshida, Y | 1 |
| Okada, K | 1 |
| Soma, M | 1 |
| Kereiakes, DJ | 1 |
| Izzo, JL | 1 |
| Littlejohn, T | 1 |
| Melino, M | 1 |
| Lee, J | 1 |
| Fernandez, V | 1 |
| Heyrman, R | 1 |
| Nishimura, H | 1 |
| Ideura, T | 1 |
| Yasuda, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389] | Phase 3 | 2,500 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
(NCT00649389)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -17.8 |
| OM40/HCTZ25 | -16.5 |
| AML10/HCTZ25 | -14.8 |
| OM40/AML10/HCTZ25 | -21.5 |
(NCT00649389)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -31.1 |
| OM40/HCTZ25 | -31.2 |
| AML10/HCTZ25 | -28.9 |
| OM40/AML10/HCTZ25 | -38.1 |
(NCT00649389)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| OM40/AML10 | 46.0 |
| OM40/HCTZ25 | 46.6 |
| AML10/HCTZ25 | 34.9 |
| OM40/AML10/HCTZ25 | 64.3 |
(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| AML10/HCTZ25 | -10.7 | -18.5 |
| OM40/AML10 | -13.9 | -23.5 |
| OM40/AML10/HCTZ25 | -18.0 | -30.3 |
| OM40/HCTZ25 | -14.5 | -23.9 |
4 reviews available for amlodipine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Amlodipine Compared with Benidipine in the Management of Hypertension: A Systematic Review and Meta-Analysis.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 2020 |
Feline comorbidities: The intermingled relationship between chronic kidney disease and hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Cat Diseases; Cats; Comorbidity; Hyper | 2021 |
Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Topics: Age Factors; Amlodipine; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; | 2013 |
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa | 2014 |
13 trials available for amlodipine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of additional vasodilatory or nonvasodilatory treatment on renal function, vascular resistance and oxygenation in chronic kidney disease: a randomized clinical trial.
Topics: Amlodipine; Angiotensins; Antihypertensive Agents; Disease Progression; Glomerular Filtration Rate; | 2019 |
The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin Receptor Antagonists; Calcium | 2013 |
Stenting and medical therapy for atherosclerotic renal-artery stenosis.
Topics: Aged; Amlodipine; Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic A | 2014 |
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Dihydropyridines; Female; Glomerular Filtratio | 2014 |
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2015 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2009 |
Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyper | 2010 |
Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel | 2012 |
Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Antioxidants; B | 2012 |
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Double-B | 2012 |
Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2007 |
11 other studies available for amlodipine and Chronic Kidney Diseases
| Article | Year |
|---|---|
[Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Combinations; Humans; Hy | 2021 |
[Swelling of the labial gingiva of the teeth].
Topics: Amlodipine; Child; Gingiva; Humans; Hypertension; Male; Renal Insufficiency, Chronic | 2023 |
Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Diabetes Mellitus; Hy | 2023 |
Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; China; Cohort S | 2018 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug | 2014 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoa | 2015 |
[EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Femal | 2015 |
[Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinat | 2015 |
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions | 2016 |
Assessment on antihypertensive effect and safety of nifedipine controlled-release tablet administered at 80 mg/day in practical clinic.
Topics: Adult; Age Factors; Aged; Ambulatory Care Facilities; Amlodipine; Antihypertensive Agents; Blood Pre | 2012 |